Literature DB >> 8139045

The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure.

L Buonaguro1, F M Buonaguro, G Giraldo, B Ensoli.   

Abstract

We have previously shown that the Tat protein of human immunodeficiency virus type 1 (HIV-1) transactivates tumor necrosis factor alpha and beta (TNF alpha and TNF beta) gene expression in HIV-1-infected and in tat-transfected T-lymphocytic and monocytic cell lines. The product encoded by the first exon of the tat gene (amino acids 1 to 72) is sufficient for this transactivation. Here we show that (i) the NF-kappa B and Sp1 binding sites of the TNF beta promoter are required for Tat-mediated transactivation and (ii) a predicted stem-loop structure in the TNF beta mRNA leader region, which resembles the Tat-responsive element of the HIV-1 long terminal repeat (TAR) and which is therefore termed TAR-like, is essential for TNF beta transactivation by Tat. These data suggest that similar promoter regulatory elements are necessary for Tat-mediated transactivation of both TNF beta and HIV-1 gene expression. This represents the first demonstration of a cellular gene with a regulatory element downstream of the transcriptional initiation site that, like TAR, may function as an RNA element.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8139045      PMCID: PMC236745     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication.

Authors:  A I Dayton; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

2.  Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I.

Authors:  M Siekevitz; S F Josephs; M Dukovich; N Peffer; F Wong-Staal; W C Greene
Journal:  Science       Date:  1987-12-11       Impact factor: 47.728

3.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.

Authors:  S Y Kao; A F Calman; P A Luciw; B M Peterlin
Journal:  Nature       Date:  1987 Dec 3-9       Impact factor: 49.962

4.  Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a viral sequence encoding 58 amino acids and lacks tissue specificity.

Authors:  L J Seigel; L Ratner; S F Josephs; D Derse; M B Feinberg; G R Reyes; S J O'Brien; F Wong-Staal
Journal:  Virology       Date:  1986-01-15       Impact factor: 3.616

5.  HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA.

Authors:  M B Feinberg; R F Jarrett; A Aldovini; R C Gallo; F Wong-Staal
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

6.  Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein.

Authors:  M A Muesing; D H Smith; D J Capon
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

7.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells.

Authors:  G Nabel; D Baltimore
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

8.  Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I.

Authors:  S L Cross; M B Feinberg; J B Wolf; N J Holbrook; F Wong-Staal; W J Leonard
Journal:  Cell       Date:  1987-04-10       Impact factor: 41.582

9.  Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1.

Authors:  K A Jones; J T Kadonaga; P A Luciw; R Tjian
Journal:  Science       Date:  1986-05-09       Impact factor: 47.728

10.  Human immunodeficiency virus long terminal repeat responds to T-cell activation signals.

Authors:  S E Tong-Starksen; P A Luciw; B M Peterlin
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

View more
  31 in total

1.  Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1.

Authors:  Marta J Gonzalez-Hernandez; Michael D Swanson; Rafael Contreras-Galindo; Sarah Cookinham; Steven R King; Richard J Noel; Mark H Kaplan; David M Markovitz
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  Recombinant human immunodeficiency virus type 1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture.

Authors:  C Neuveut; K T Jeang
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

3.  Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1.

Authors:  F Demarchi; F d'Adda di Fagagna; A Falaschi; M Giacca
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

4.  A stimulation-dependent alternate core promoter links lymphotoxin α expression with TGF-β1 and fibroblast growth factor-7 signaling in primary human T cells.

Authors:  Brian H Yokley; Sandra T Selby; Phillip E Posch
Journal:  J Immunol       Date:  2013-04-01       Impact factor: 5.422

5.  Purification and characterization of FBI-1, a cellular factor that binds to the human immunodeficiency virus type 1 inducer of short transcripts.

Authors:  F Pessler; P S Pendergrast; N Hernandez
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

6.  Morphological, histochemical, immunohistochemical, and ultrastructural characterization of tumors and dysplastic and non-neoplastic lesions arising in BK virus/tat transgenic mice.

Authors:  G Altavilla; C Trabanelli; M Merlin; A Caputo; M Lanfredi; G Barbanti-Brodano; A Corallini
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

7.  Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.

Authors:  Barbara Ensoli; Stefania Bellino; Antonella Tripiciano; Olimpia Longo; Vittorio Francavilla; Simone Marcotullio; Aurelio Cafaro; Orietta Picconi; Giovanni Paniccia; Arianna Scoglio; Angela Arancio; Cristina Ariola; Maria J Ruiz Alvarez; Massimo Campagna; Donato Scaramuzzi; Cristina Iori; Roberto Esposito; Cristina Mussini; Florio Ghinelli; Laura Sighinolfi; Guido Palamara; Alessandra Latini; Gioacchino Angarano; Nicoletta Ladisa; Fabrizio Soscia; Vito S Mercurio; Adriano Lazzarin; Giuseppe Tambussi; Raffaele Visintini; Francesco Mazzotta; Massimo Di Pietro; Massimo Galli; Stefano Rusconi; Giampiero Carosi; Carlo Torti; Giovanni Di Perri; Stefano Bonora; Fabrizio Ensoli; Enrico Garaci
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

8.  A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.

Authors:  M Meyer; M Clauss; A Lepple-Wienhues; J Waltenberger; H G Augustin; M Ziche; C Lanz; M Büttner; H J Rziha; C Dehio
Journal:  EMBO J       Date:  1999-01-15       Impact factor: 11.598

9.  HIV-1 Tat mediates degradation of RON receptor tyrosine kinase, a regulator of inflammation.

Authors:  Parisa Kalantari; Omid F Harandi; Pamela A Hankey; Andrew J Henderson
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

10.  An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy.

Authors:  J Lisziewicz; D Sun; B Trapnell; M Thomson; H K Chang; B Ensoli; B Peng
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.